REVUFORJ

This brand name is authorized in United States.

Active ingredients

The drug REVUFORJ contains one active pharmaceutical ingredient (API):

1	Revumenib UNII LZ0M43NNF2 - REVUMENIB
	Revumenib is a menin inhibitor that blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of wild-type KMT2A or KMT2A fusion proteins with menin is involved in NPM1 mutated acute myeloid leukemias and KMT2A-rearranged acute leukemias, respectively, through activation of a leukemogenic transcriptional pathway.
	Read more about Revumenib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REVUFORJ Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX87		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX87

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	73555-500, 73555-501, 73555-502